Associated Papers
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
Elisei R et al.
Endocrine, 2023
RET Proto-Oncogene Variants in Patients with Medullary Thyroid Carcinoma from the Mediterranean Basin: A Brief Report.
Neocleous V et al.
Life (basel, Switzerland), 2023
Multiple endocrine neoplasia type 2 (MEN2) and RET specific modifications of the ACMG/AMP variant classification guidelines and impact on the MEN2 RET database.
Margraf RL et al.
Human Mutation, 2022
GLOBAL ENDOCRINOLOGY: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review.
Maciel RMB et al.
European Journal of Endocrinology, 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D et al.
Nature Reviews. Endocrinology, 2021
Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer.
Chiacchiarini M et al.
Pharmacology & Therapeutics, 2021
Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas.
Sarkadi B et al.
Cancers, 2020
Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer.
Machens A et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2019
Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients.
Pezzani R et al.
International Journal of Endocrinology, 2019
Actionable secondary findings from whole-genome sequencing of 954 East Asians.
Tang CS et al.
Human Genetics, 2018
Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.
Cavedon E et al.
International Journal of Endocrinology, 2017
Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.
Pelizzo MR et al.
American Journal of Clinical Oncology, 2015
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C et al.
Clinical Endocrinology, 2015
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells SA et al.
Thyroid : Official Journal of the American Thyroid Association, 2015
In silico analysis of RET variants in medullary thyroid cancer: from the computer to the bedside.
Heineman TE et al.
Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-head and Neck Surgery, 2015
Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma.
Crona J et al.
Plos One, 2015
The value of genetic screening in medullary thyroid cancer.
Pappa T et al.
Expert Review of Endocrinology & Metabolism, 2014
Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours.
Crona J et al.
Plos One, 2014
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Wells SA et al.
The Journal of Clinical Endocrinology and Metabolism, 2013
High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients.
Imai T et al.
European Journal of Endocrinology, 2013
Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests.
Camacho CP et al.
Thyroid : Official Journal of the American Thyroid Association, 2013
Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.
Crockett DK et al.
Genome Medicine, 2012
RET codon 609 mutations: a contribution for better clinical managing.
Mian C et al.
Clinics (sao Paulo, Brazil), 2012
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.
Romei C et al.
Journal of Oncology, 2012
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.
Waguespack SG et al.
Nature Reviews. Endocrinology, 2011
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
Romei C et al.
European Journal of Endocrinology, 2010
Analysis of RET, ZEB2, EDN3 and GDNF genomic rearrangements in central congenital hyperventilation syndrome patients by multiplex ligation-dependent probe amplification.
Serra A et al.
Annals of Human Genetics, 2010
RET germline mutations in codon 609 and MEN2A phenotype: are they all created equal?
Machens A et al.
Annals of Surgical Oncology, 2010
Multiple endocrine neoplasia type 2.
Lips CJ et al.
Expert Review of Endocrinology & Metabolism, 2009
When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
Calva D et al.
Annals of Surgical Oncology, 2009
Analysis of RET, ZEB2, EDN3 and GDNF genomic rearrangements in 80 patients with Hirschsprung disease (using multiplex ligation-dependent probe amplification).
Serra A et al.
Annals of Human Genetics, 2009
Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation.
Mian C et al.
Familial Cancer, 2009
Histopathologic and clinical features of medullary microcarcinoma and C-cell hyperplasia in prophylactic thyroidectomies for medullary carcinoma: a study of 42 cases.
Etit D et al.
Archives of Pathology & Laboratory Medicine, 2008
RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.
Margraf RL et al.
The Journal of Molecular Diagnostics : Jmd, 2007
[Molecular biology, basic research and diagnosis of Hirschsprung's disease].
Martucciello G et al.
Der Pathologe, 2007
Genotype-phenotype correlations in Hungarian patients with hereditary medullary thyroid cancer.
Patocs A et al.
Wiener Klinische Wochenschrift, 2006
Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients.
Fernández RM et al.
International Journal of Molecular Medicine, 2006
RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
Asai N et al.
Pathology International, 2006
Masking selected sequence variation by incorporating mismatches into melting analysis probes.
Margraf RL et al.
Human Mutation, 2006
Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
Kinlaw WB et al.
Clinical Endocrinology, 2005
Interaction of RET proto-oncogene codon 609 germline mutations with RET haplotypes characterized by c.135G>A alleles modifying MEN 2A or HSCR phenotypes.
Fitze G et al.
American Journal of Medical Genetics. Part A, 2004
Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease.
Fitze G et al.
Lancet (london, England), 2002